A Memorial Sloan-Kettering team has honed a protocol for producing large quantities of human dopaminergic neurons that could be grafted into patients with PD or used as a screening platform for the disease. Scaling up the protocol remains a challenge, and demonstrating safety will be a prerequisite for therapeutic development.